# A Phase 1/2 Study to Evaluate MEDI4736

> **NCT01693562** · PHASE1,PHASE2 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 1022 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** MEDI4736

## Key facts

- **NCT ID:** NCT01693562
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09-05
- **Primary completion:** 2020-02-28
- **Final completion:** 2020-02-28
- **Target enrollment:** 1022 (ACTUAL)
- **Last updated:** 2021-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01693562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01693562, "A Phase 1/2 Study to Evaluate MEDI4736". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01693562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*